Compositions and methods for treating iron overload
AssigneeLa Jolla Pharmaceutical Company
InventorsGeorge Tidmarsh, Lakhmir Chawla
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of hepcidin, mini-hepcidin, or a hepcidin analogue in therapeutic methods for the treatment and/or prevention of acquired iron overload or other conditions for which iron redistribution or sequestration is helpful.
Claims132
A method of treating and/or preventing acute kidney injury in a subject by administering a composition comprising hepcidin or mini-hepcidin to the subject.
A method of treating and/or preventing insulin resistance in a subject by administering a composition comprising hepcidin or mini-hepcidin to the subject.
A method of treating and/or preventing insulin insufficiency in a subject by administering a composition comprising hepcidin or mini-hepcidin to the subject.
A method of treating and/or preventing a condition associated with reduced iron absorption by bone marrow in a subject by administering a composition comprising hepcidin or mini-hepcidin to the subject.
A method for treating acquired iron overload in a subject, comprising administering a composition comprising hepcidin or mini-hepcidin to the subject.
A method for preventing iron overload in a subject undergoing a blood transfusion comprising administering a composition comprising hepcidin or mini-hepcidin to the subject.
The method of any one of the preceding claims, wherein the subject is a mammal.
A method for treating and/or preventing a condition in a subject, comprising administering a composition comprising hepcidin or mini-hepcidin to the subject.
A method of reducing, preventing, or reversing organ damage or enhancing organ preservation comprising administering a composition comprising hepcidin or mini-hepcidin to an organ donor prior to removal of the organ.
A method of reducing, preventing, or reversing organ damage or enhancing organ preservation comprising contacting the organ with a preservation solution wherein the preservation solution comprises a composition comprising hepcidin or mini-hepcidin.
A method of facilitating an organ transplant procedure or enhancing the success of an organ transplant procedure, comprising contacting the organ ex vivo with a preservation solution wherein the preservation solution comprises a composition comprising hepcidin or mini-hepcidin.
A method of prolonging organ viability ex vivo, comprising contacting the organ ex vivo with a preservation solution wherein the preservation solution comprises a composition comprising hepcidin or mini-hepcidin.
A method of treating and/or preventing a condition in a subject by administering a composition comprising hepcidin or mini-hepcidin to the subject, wherein the condition is insulin resistance, insulin insufficiency, carotid artery lesion, chronic kidney disease, acute kidney injury, proteinuria, anti-glomerular basement membrane (anti-GMB) glomerulonephritis, minimal change disease, membrane nephropathy, autoimmune glomerulonephritis, or a condition associated with reduced iron absorption by bone marrow.
A method of reducing total body iron in a subject by administering hepcidin or mini-hepcidin to the subject.
Dependencies are inferred from the claim text.